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The  Arg residue at position 8 of mammalian  GnRH is 
necessary for high  affinity  binding to mammalian GnRH 
receptors.  This requirement has been  postulated to de- 
rive from an electrostatic interaction of Arg with a 
negatively charged receptor residue.  In order to identify 
such a residue, 8 conserved  acidic residues of the mouse 
GnRH receptor were mutated to isosteric Asn or Gln. 
Mutant receptors were tested for decreased  preference 
for Arg-containing ligands by ligand  binding and inosi- 
tol phosphate production. 
One of the mutants, in which the GluSo1 residue was 
mutated to  Gln,  exhibited a 56-fold decrease in apparent 
affinity for mammalian GnRH. The mutant receptor also 
exhibited  decreased  affinity  for [Lyss]GnRH, but  its af- 
finity for [GldIGnRH was unchanged compared with 
the wild  type  receptor.  The apparent affinity of the mu- 
tant receptor for the acidic  analogue, [Glus]GnRH,  was 
increased more than 10-fold.  The mutant receptor did 
not, therefore, distinguish mammalian GnRH from ana- 
logues  with  amino  acid substitutions at position 8 as 
effectively as the wild type  receptor.  This  loss of dis- 
crimination was  specific  for the residue at position 8, 
because the mutant receptor did distinguish mamma- 
lian GnRH from analogues  with  favorable substitutions 
at positions  5,6, and 7. These  findings  show that Gluso' of 
the GnRH receptor plays a role in receptor recognition 
of A r ~  in the ligand and are consistent with an electro- 
static interaction between these 2 residues. 
The  hypothalamic decapeptide,  gonadotropin-releasing hor- 
mone  (GnRH)' is  the  central  regulator of reproductive  function. 
The  structures of the  amino  and carboxyl termini of GnRH 
have been  conserved over 500 million years of evolution. The 
most variable  residue is at position 8. In  mammalian GnRH 
this is a positively charged Arg residue, which is  necessary for 
high affinity and specificity of binding to mammalian GnRH 
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receptors (GnRHR). In  contrast,  GnRHs from  most  non-mam- 
malian  vertebrates  contain  uncharged  residues at position 8 
(1). Although these  non-mammalian GnRHs are fully  active in 
the  animals  in which they occur naturally,  they show  dimin- 
ished capacity to  stimulate  release of gonadotropins  from mam- 
malian  pituitary cells (1) and  to  stimulate inositol phosphate 
(IP) production in cells transfected  with  mammalian GnRHRs 
(2). Experiments  using  synthetic GnRH analogues  have con- 
firmed  the  importance of a positively charged  amino acid at 
position 8 for high affinity interaction  with  mammalian Gn- 
It   has been  postulated that the ArgS side  chain  may  interact 
directly with  the GnRHR via an electrostatic  interaction  with a 
negatively  charged  Asp or  Glu  residue (6) or with a sialic  acid 
residue in the  carbohydrate moiety of this glycoprotein (7). A 
functional GnRHR was  first cloned from the mouse aT3 gona- 
dotroph cell line (8). This  and  the  subsequent cloning of three 
other  mammalian GnRHRs (2, 9-13) have allowed the appli- 
cation of site-directed mutagenesis  in identifying amino acid 
residues which determine the specificity of mammalian Gn- 
RHRs for GnRHs  which contain Arg at position 8. 
The  ligand  binding  sites of heptahelical G-protein-coupled 
neurotransmitter receptors are contained within the trans- 
membrane helical bundle (14, 15). However, the  larger size of 
peptide  hormones  suggests that the  extracellular loops of their 
receptors may  also  participate  in ligand binding functions. To 
test  the possibility that the  high affinity of mammalian GnRH, 
which contains Arg, is dependent on an acidic residue, we 
systematically  mutated conserved acidic residues  in  the  extra- 
cellular  and  transmembrane  domains of the mouse GnRHR. 
We show here  that one of these  mutant receptors, the 
[Gln30']GnRHR, displayed  decreased ligand  binding affinity  for 
mammalian GnRH, but affinities for GnRH analogues with 
uncharged  residues a t  position 8 were  unchanged  or increased. 
RHRs (3-5). 
MATERIALS AND METHODS 
Peptides-GnRH, [Gln'lGnRH (chicken GnRH I), chicken GnRH I1 
([His5,Trp7,Tyr'lGnRH), [D-A~~~,N-N"~-L~U~,P~O~-NHE~IG~RH, [~-Trp'l- 
GnRH, [D-T~~~ ,P~O~-NHE~IG~RH,  and [ D - T ~ ~ ~ , G ~ ~ ~ , P ~ O ~ - N H E ~ I G ~ R H  
were prepared by conventional  solid-phase  methodology and  purified by 
preparative C-18 reversed-phase chromatography. [Glu'lGnRH and 
[His'IGnRH  were gifts from R. W. Roeske and [Lys81GnRH was a gift 
from J. Rivier. 
Mutagenesis  and ZFansfection-The mouse GnRHR  was  cloned into 
pBluescript I1 SK' (Stratagene, La Jolla, CA) and site-directed mu- 
tagenesis was  performed  using  uracil-containing DNA (16) for 
[Glns]GnRHR,[Gln111]GnRHR,[Asn's6lGnRHR,[Asn292lGnRHR,~Gln294l- 
GnRHR, and [Gln301]GnRHR. For [GlngOJGnRHR and [Asn9'lGnRHR, 
the mouse GnRHR  was  cloned into the PALTERTM-1  vector  and mutated 
using  altered sites in vitro mutagenesis  system  (Promega). To confirm 
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(U. S, Biochemical Corp,) or by automated sequencer (Bio-Rad). The 
receptor was subcloned into the expression vector pcDNMAmp (In- 
vitrogen Corp., San Diego,  CA), and  mutation  sites were resequenced. 
COS-1  cells  were transiently transfected with pcDNAI/Amp-GnRHR 
constructs using a modification of the DEAE-dextran method (17) as 
described  previously (12). 2.5 pg of  DNA construct was used  per  well in 
12-well plates for IP assays and 15 pg of DNMlO-cm dish for ligand 
binding assays. Receptor expression ranged from 150 to 600 fmo1/106 
cells  for the wild type GnRHR and from  35 to 150 fmol/106 cells for the 
[Gln3011GnRHR. 
IP Production-Transfected cells were labeled overnight with 
[H3]inositol (2 pCi/ml) and stimulated with GnRH or GnRH analogues 
for 60 min in  the presence of LiCl(10 m). The reaction was terminated 
by addition of a perchloric  acid solution and phytic acid.  After neutral- 
izing with KOH, inositol phosphates were separated on Dowex ion 
exchange columns and counted (18). 
Radioligund Binding Assay-Ligand binding assays with the wild 
type GnRHR and the screening ligand binding assay were  performed as 
described previously (12). Briefly, transfected COS-1 ceIls were de- 
tached from culture dishes in binding buffer (10 mt =PES, pH  7.4, l 
iil~ EDTA, 0.1% BSA, fatty acid-free), homogenized with a Dounce 
homogenizer, and centrifuged at  15,000 x g  for  30 min at  4 "C. The crude 
membrane pellet was resuspended in binding buffer and incubated (7.5 
x lo5 cell  eqftube,  -200  fmol of receptor) with 60,000 cpm of 12,1-to- 
~ a 6 ~ - M e - ~ u ' , ~ ' - N H E t 1 G n R H  (-50 p ~ f  and varying concentra- 
tions of unlabeled test peptides in a final volume of 0.5 ml for 60-90 min 
on ice. The i n ~ b a ~ o n  was terminated by the addition of 3 ml  of phos- 
p h a ~ - b ~ e r e d  saline (PBS,  pH 7.5) containing 0.1% BSA and immedi- 
ate filtration through glass fiber filters (GFIC,  atm man) presoaked in 
PBS containing 1% BSA. The filters were washed twice with 0.1% 
BSA-PBS, and the retained radioactivity was counted. Nonspecific 
binding was estimated in the presence of 10"' M unlabeled [D-A1a6J?- 
M e - ~ u 7 , ~ o w - ~ H E t J G ~ .  
To compensate for the lower total binding of ~~61-[~Ala6JV-Me- 
~ u 7 , P r o 9 - ~ ~ t J G n ~  exhibited by the [G~n3*I]GnR~,  higher concen- 
trations of membranes (1.2 x lo6 cell eqitube, -75 fmol of receptor) were 
used for subsequent experiments on the  mutant receptor. Also, to avoid 
dissociation of the labeled ligand from the lower affinity receptor, the 
dilution step  at  the end of the  assay was eliminated and the Elters 
washed four times under vacuum with 0.1% BSA-PBS to remove  non- 
specifically  bound *251-f~AlasJV-Me-Leu7,Pras-~Et]G~,  Increasing 
amounts of the ~ C D N M ~ ~ - [ G I ~ ~ ~ ~ I G ~ R H R  construct in the transfec- 
tion reaction showed that maximal expression of the mutant receptor 
was achieved with 15 pg of  DNMlO-cm dish of cells, the same as with 
the wild type GnRHR construct. Binding of '251-I~-AlaE~-Me-Leu',Prog- 
NHEtlGnRH was maximal &er incubation for 75 min and remained 
stable for a further 75 min.  Specific  binding ranged from  2004 to 4518 
cpdtube (0.8-1.9 fmol,  compared with 11,700 to 20,543 cpdtube, 4.8- 
8.6 fmol, with wild type GnRHR), whereas nonspecific binding ranged 
from 2189 to 3228 cpdtube (0.9-1.3  fmol). 
inhibit binding of 1251-[~-Ala6,N-Me-Leu7,ProQ-NHEt]GnRH (IC8,, val- 
Data Analysis-Peptide concentrations required to half-maximally 
ues)  and to stimulate half-maximal IP production (EC,, values) were 
estimated by four-parameter nonlinear curve fitting using Sigmaplot 
(Jandel Scientific,  Corte Madera, CA). Binding assays were  performed 
in triplicate, and IC,, values were determined in three to  five independ- 
ent experiments. IC,, data  in Table I are means % S.E. of all experi- 
ments. Competitive binding curves for  some  GnRH peptides exhibited 
slopes which render Hill  coefficients not equal to  one.  For this reason, 
we have used IC,, values as indicators of apparent ligand binding af- 
finity and supported our observations of changes in apparent afflnity by 
measuring ED,, values for IP production in response to all GnRH  pep- 
tides. IP assays were performed in duplicate, and EC,, values were 
determined in two or three independent experiments. EC,, data in 
Table I are the mean e S.E. of all experiments. For Figs. 3-6, individual 
IP  and binding data points from all experiments were averaged, and 
curves were drawn using four-parameter nonlinear curve-fitting as 
above. 
RESULTS 
Identification of a Mutant GnRHR Which  Does Not Discrimi- 
nate GnRH and [Gln8]GnRH-We identified 8 acidic amino 
acid residues (Fig. 1) in  the extracellular and superficial trans- 
membrane domains of the mouse  GnRHR  which are conserved 
as acidic residues in  all of the cloned  GnRHRs and which were 
therefore candidates for interaction  with Arg@ of GnRH. If the 
-NH2 
structure of tbe rnou~e GnRSR. Conserved  acidic residues in the 
FIG. 1. The amino acid sequence and proposed secondary 
extracellular and superficial transmembrane domains are indicated by 
their sequence numbers and bold ~ y ~ ~ u c e .  
Ar$ of GnRH were to interact directly with one of the acidic 
residues of its receptor, a mutant GnRHR in which this inter- 
action i s  disrupted would be expected to have low affinity for 
the ' z 5 1 - [ ~ - ~ a 6 ~ - ~ e - ~ u 7 , ~ o a - N H E t ] G n R H  used in  the recep- 
tor binding assay. Because this decreased affinity would result 
in low specific binding of the labeled GnRH agonist, mutant 
GnRHRs were first screened for their ability to s u p p o ~  GnRH- 
stimulated IP production. M GnRH is just s ~ l c i e n t  o 
cause maximal IP production in the wild type GnRHR. A mu- 
tant GnRHR with decreased affinity for GnRH, but normal 
coupling to phospholipase C, should exhibit decreased IP pro- 
duction in response to lo-* M GnRH, but a normal maximal 
response to M GnRH. 
Systematic substitution of 6 acidic residues, Glu', Gluw, 
Glu"', Aspxa5, Asp292, and GluZg4, with their isosteric amides did 
not  cause  large changes in the ability of the  mutant GnRHRs to 
support GnRH-stimulated IP production (Fig. 2). Tvvo GnRHR 
mutants, [As~$~]G~RHR and [G1n3O11GnRHR, demonstrated re- 
duced IP production in response to M GnRH (Fig. 2). Of 
these, only the [Gln3O11GnRHR demonstrated a full response to 
M GnRH (Fig. 2). In a screening ligand binding assay, all 
mutant GnRHRs except [Asng']GnRHR exhibited specific 
binding of 1251-[~-Ala6,N-Me-Leu7,Prog-NHEt]GnRH (data not
shown). 
In competitive ligand binding assays the [Gln3'']GnRHR 
showed decreased apparent affinity for  GnRH, but  the appar- 
ent affinity for {Gln'IGnRH was similar to that of the wild type 
receptor (Table I; Fig. 3). Both peptides showed low potency in 
stimulating IP production in COS-1 cells transfected with the 
LGln3"lGnRHR with very similar dose-response curves (Table 
I; Fig. 3). 
Activities of Other Position 8-substituted GnRHs-GnRH 
analogues with Lys, His, or Glu substituted for Arg@ exhibited 
low apparent affinities for the wild type GnRHR.  [Lys*]GnRH 
was most potent, whereas the negatively charged [Glu'JGnRH 
was least potent, being unable to cause 50% inhibition of bind- 
ing of the labeled GnRH agonist at concentrations up to lo4 M 
(Table I; Fig. 4). Apparent affinities of these peptides for the 
mutant [Gln3"1GnRHR were also low. The mutant receptor 
exhibited 3-fold decreased affinity for the positively charged 
[Lys'lGnRH and increased affinities for [His'IGnRH and for 
[Glu81GnRH (Table I; Fig. 4). 
Consistent with the ligand binding results, GnRH analogues 
with Lys and His residues at  position 8 were less potent in 
stimulating IP production with the [Gln301]GnRHR than with 
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COS-1 cells transfected with GnRHR mutants in which con- 
FIG. 2. Screening  assay for GnRH-stimulated IP production  in 
served  acidic  residues  were  mutated  to A m  or Gln. Transfections 
were  performed as described under "Materials and Methods." Mutant 
receptors are identified by the name of the new residue (Gln or Asn) and 
its sequence number. Wt is the wild type mouse GnRHR. IP production 
was measured in the absence of GnRH (open  bars) and in the presence 
of lo-' M (solid bars) and M GnRH (cross-hatched bars). 
reduction in potency (Table I; Fig. 4). [Glu'IGnRH did not 
stimulate maximal IP production in cells transfected with 
either wild type or mutant receptors  (Fig. 4). Thus,  mammalian 
GnRH and  all position 8-substituted GnRH  analogues showed 
low potency in  activating  the  mutant GnRHR (Table I; Fig. 4). 
Other GnRH Agonists-Low affinity  binding interactions  are 
generally less specific than high  affinity  interactions. Thus, a 
mutation which causes  general  disruption of the configuration 
of the ligand  binding site,  rather  than  eliminating a specific 
interaction, could generate a low affinity  receptor which also 
does not discriminate different  GnRH  analogues, as  was found 
for the [Gln30'lGnRHR. To test  whether  this loss of discrimina- 
tion  was specific for modifications of GnRH at position 8, the 
activities of GnRH  analogues which have high  affinity due to 
modifications of other  residues were tested. Chicken GnRH I1 
([His5,Trp7,Tyr'lGnRH) and two conformationally constrained 
GnRH superagonists, [D-A~~'JV-M~-L~~'',P~O~-NHE~]G~RH 
and [D-T~P'IG~RH, showed higher apparent affinity for the 
[Gln3O11GnRHR than did GnRH or analogues  containing  sub- 
stitutions only at position 8 (Table I; Fig. 5) .  These peptides 
were  also  more  active than GnRH and [Gln'IGnRH in  stimu- 
lating IP production in cells transfected with the [Gln3O11- 
GnRHR (Table 1; Fig. 5) .  Thus,  the [Gln3O']GnRHR exhibited 
high  affinity for GnRH agonists containing favorable substitu- 
tions at positions 5,  6, 7, and 10 and  was  able to  discriminate 
between them and GnRH. This indicates specific loss of an 
interaction which requires Ar$, rather  than a generalized de- 
crease  in  binding affinity. 
Superagonists with and without  Arg-Having  identified  a 
residue (Glu301) in  the GnRHR which determines  the specificity 
of the receptor for ArgS in GnRH, we addressed the question of 
whether  this specificity depended on a direct interaction be- 
tween the side chains of the Ar$ and Gluaol residues or on the 
intramolecular function of&$ in stabilizing the preferred con- 
formation of GnRH. To do this we attempted to discount the 
intramolecular role of Ar$ by comparing the activities of two 
high affinity GnRH agonists ( [ D - T ~ ~ ' , P ~ O ~ - N H E ~ I G ~ R H  and 
[D-T~~',G~~~,P~~~-NHE~]G~RH) in which the  preferred confor- 
mation is constrained by ~ - T r p  at position 6 and which differ 
from each other only at  position 8. Both  peptides  exhibited  high 
affinity  binding to both wild type  and  mutant receptors. The 
Gins-containing peptide showed higher apparent affinity for 
the  mutant [Gln30']GnRHR than for the wild type receptor (Ta- 
ble I; Fig. 6). The Gln'-containing peptide  also  exhibited no loss 
of potency in  stimulating  IP production in  the  mutant receptor 
compared with wild type (Table I; Fig. 6). The  rank  order of 
potency of the two peptides was reversed in  the [Gln3"1GnRHR, 
with  the Gln8-containing  peptide more potent than  the kg- 
containing  peptide in stimulating IP production, although 
binding  affinities  were similar for both  peptides (Table I; Fig. 
6). These results  indicate  that  the mechanism by which the 
Glu301 residue confers specificity for kg@ is more complex than 
either a  simple  electrostatic interaction or simple  stabilization 
of ligand conformation. 
DISCUSSION 
Eight GnRHR mutants were constructed, in which acidic 
residues in  the superficial transmembrane  and  extracellular 
domains were exchanged for uncharged  hydrophilic amide resi- 
dues  with  equivalent  side  chain lengths. Six mutant GnRHRs 
exhibited normal GnRH-stimulated IP production in a  screen- 
ing assay, whereas two mutations caused  changes in IP pro- 
duction. Mutation of Aspg8 caused  a loss of both  agonist  ligand 
binding  and GnRH-stimulated IP production, suggesting  that 
this  mutation may affect expression or stability of the receptor 
or disrupt  the configuration of the ligand  binding site. 
The [Gln3O11GnRHR mutant had characteristics consistent 
with loss of specificity for Arg at position 8 of GnRH. It exhib- 
ited low apparent affinity for GnRH, similar  to  the low appar- 
ent affinity of the wild type receptor for GnRH analogues which 
do not contain Arg at position 8. Its apparent affinity for 
[Gln'IGnRH was  unchanged from that of the wild type receptor 
for this ligand. However, its  apparent affinity for [GluslGnRH 
was more than 10-fold higher  than  that of the wild type recep- 
tor. The  mutant receptor  did not clearly distinguish GnRH from 
analogues which have  substitutions exclusively at position 8. 
Since low affinity interactions often lack specificity, it  might  be 
argued  that  the [Gln301]GnRHR is simply a low affinity  receptor 
which has lost the ability to discriminate different ligands. 
However, the [Gln301]GnRHR retained  appropriate affinities for 
GnRH analogues which contain activating substitutions in 
other positions. Thus, removal of the negatively  charged Glu301 
residue of the GnRHR removed the preference of the receptor 
for Arg at position 8 of GnRH, but  it did not remove the pref- 
erence of the receptor for ligands  with favorable substitutions 
at positions 5 and 7, as illustrated by chicken GnRH 11, nor did 
it remove the preference for a D-amino acid at position 6. Thus 
the GIu3O1 residue of the mouse GnRHR determines  the ability 
of the receptor to recognize ArgS in GnRH. 
It  has been proposed that  the ArgS of GnRH participates  in a 
direct ionic interaction with 1 or more negatively  charged  resi- 
dues  in  the receptor, either  an amino acid side  chain ( 6 )  or a 
polysaccharide sialic acid residue (7). The present  results, com- 
bined with our recent  demonstration  that  mutation of each of 
the  putative glycosylation sites  in  the GnRHR does not affect 
ligand  binding affinity,' support  the involvement of an amino 
acid side chain,  rather  than a  sialic acid residue, in  the  inter- 
action of the GnRHR with Ar$. 
An electrostatic interaction is also supported by the experi- 
ments with [Glu'IGnRH which has a negatively  charged resi- 
due at position 8. The very low binding affinity (IC6o > M) 
of the wild type GnRHR for [GluslGnRH is consistent with 
repulsion  between the negative charges of Glu' in  the peptide 
and Glu301 in  the GnRHR. Removing the negative charge of the 
amino acid at position 301 of the receptor improved the  appar- 
ent binding  affinity of this negatively  charged  ligand more than 
10-fold (IC5o, 2.21 x M in the [Gln3"]GnRHR). 
However, the mechanism by which specificity for Ar.$ is con- 
ferred by Glu301 appears more complex than a  simple electro- 
static interaction.  Like many peptides,  GnRH is highly flexible 
in solution and  exists as an equilibrium mixture of structural 
conformers. It  has been proposed that  the side  chain o f k g  
stabilizes a preferred conformation of GnRH by forming a 
structural  unit of hydrogen  bonding  with the side chains of His2 
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TABLE I
Summary of ligand  binding  and  IPproduclion results 
WiId type GnRHR II ~ G ~ n 3 O i 1 G n R ~ ~  
Peptide 
Activity index5 
1% E%, 1%” ECSO Binding IP 
GliR€i 20.9 i_ 7.9 1.14 t 0.02  118  f 74  333 2 80  56.5 292
n.w RH 
~ ~ y s * ~ G n ~  1050 I 254 86.4 f 30.0 3290 4 494 1420 2 320 3.13 16.4 
FGln*JGnRH 2530 k 175 42.0 t 2.5 1870 rt 498 369 t 61 0.74 8.78 
tHis6jGnRH 4630 2 1410 311 t 140 950 2 388 1010 f 410 0.21 3.25 
fGlu8JGnRH >lo5 1160 -C 180 22100 f 4410 1750 f 460 <0.2 1.51 
~ ~ s ~ , ~ ~ , ~ * ~ G ~ R  (chicken GnRsI 11) 48 t 10 5.3 f 1.5 106 t 32.2 29.4 I 9.0 2.21 5.5 
6.6  134 
~ 5 ~ 6 J G n R ~  2.08 i 0.42  0.095 2 0.032  1 18 L 0.37  15 9 2 3.4 0.57  167 
~~~6,Pros-NHEtlGnRH 1.86 f 0.26  0.048 f 0.007  1.38 I 0.44  3.60 t 2.47  07475
~ D - ~ ~ , G ~ ~ * , ~ * - ~ ~ ~ G ~ H  10.1 f 0.59  32 f 0.22  2. 6 i 0.64  33 2 0.04 0.22 1.03 
a Activity  index,  which  indicates  the  apparent  decrease in potency of each  peptide  due to the  mutation of Glu3’’, was calculated  as  the  ratio f 
the IC, values  (binding)  or EC, values (IP production)  in the [Gln3”]GnRNR  and  the  wild  type  GnRRR. An activity  index o f  1 indicates  identical 
actkity in both  receptors. 
G W b  1.50 I 0.35 0.074 i 0.013 7.06 t 2.44  9.90 2 0.45 
~- 
GnRHAg is [ ~ - ~ a ~ ~ - M e - L e u ~ , p ~ * - N ~ E t l G n R H .  
FIG, 3. GnfM and ~ G ~ E I G n f M  ligand  binding  and IP produc- 
tion in COS4 cetls transfected with wild type GnRHR and 
[ G ~ s o ~ l G ~ ~ .  Binding of 1 2 5 1 - ~ ~ - ~ a ~ ~ - ~ e - L e u T ~ P r o ~ N ~ E t ~ G n R H  
(top  panel) in the presence of various  concentrations o f  GnRH (0,O) and 
tGln*l~nRH (0, W to membranes prepared from COS-1 cells trans- 
fected  with  wild  type  GnRRR (- - - -, 0 , O )  or  IGlnm’JGnRHR (-, 0, V) 
was  measured  as  described  under  “Materials  and  Methods.”  Data  points 
are  the mean 2 S.E. o f  three to five experiments  performed  in  triplicate. 
IP production (lower  panel) in response to GnRH (0, V) and 
ZGlnSIGnRH (0, V) in COS-1 cells  transfected  with  wild  type  GnRHR 
rials and  Methods.”  Data  points  are the means of two or  three  experi- 
ments  performed  in  duplicate. 
and Tyr5 (19-211. It has also been shown that although this 
type of structural  unit is formed in GnRH, it is not formed in 
the  neutral [Gln81GnRH analogue (22). Other  studies  have in- 
dicated that GnRH interacts with its receptor in a folded  con- 
formation with a @-turn which involves Gly6. This conformation 
can be stabilized by subst~tution of Gly6 with a D-amino acid, 
1”” , 0,O) and 1 G ~ ~ ’ l ~ G ~ H R  (-, V, 7 )  as described  under “Mate- 
paptide (M) 
RG. 4. Ligand  binding  and IP production  of  position  8-substi- 
tuted GnRH analogues in COB1 cells transfected with wild  type 
G&HR and [Glnso’~GnRHR. Binding of 1261-[o-AlasJV-Me-Leu7, 
ProT?HEtlGnRH (top  panels) and IP production (dower panets) in the 
presence of various concentrations of &RH, FLys61GnRff,  KHis’JGnW, 
and [Glu5jGnRH in COS-1 cells  transfected  with wild type GnRHR 
(Zej-2 panels) or [Gin~I~GnRHR (right panels) were measured as de- 
scribed  under u ~ a t e r i ~ s  and ~ e t h o ~ . n  lai ding data points are  the 
mean +: S.E. of three  to five expe~ments p e ~ o ~ e d  in triplicate,  and 
IP data points  are the means of two or three e x p e ~ m e n ~  performed in 
duplicate. 
which increases GnRH activity (23-25). Therefore, i f  My6 in 
G&H is substituted with ~-Trp, the ligand can be constrained 
in the preferred c o ~ o ~ a t i o n ,  i dependently of whether or not 
there is Arg at position 8. This  constraint  makes it possible to 
~ s t i n ~ i s h  the rote of Ar$ in ~nteracting with the receptor 
G ~ u ~ ~ ~  residue from its cont~but~on to ligand stabilization. 
Thus, we compared the  apparent binding affinities, in wild 
type and  mutant receptors, of two conformationally con- 
strained GnRH agonists ([D-T~~‘,P~o’-NHE~IG~RH  and 
[ D - T ~ ~ ~ , G ~ ~ ~ , P ~ ~ - N H ~ ~ ] G ~ ~ )  which are identical except for
the substitution of Gln for k g  a t  position 8. If there were a 
simple electrostatic interaction between Ar$ and Glu301,  con- 
strained analogues would  be  expected to show the same losses 
of affinity as did the unconstrained peptides. Thus, the affinity 
of the wild type GnRI5.R for the constrained analogue containing 
Gln at position 8 should be  50-fold  lower than its affinity for the 
constrained Ar$ analogue. Also the  mutant receptor should ex- 
hibit  similar lower affinities for both constrained peptides. In 
contrast, if there is no electrostatic interaction between these 
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FIG. 5. The  mutant  [GlnSo’]GnRHR exhibits wild type specific- 
ity for GnRH analogues  with  substitutions  at  positions 6, 6, 7, 
and 10. Binding of ‘251-lo-Alas;Y-Me-Leu7,Pro3~EtlGnRH (top panel) 
and I~production ( ~ o w e r ~ u ~ e Z )  in  the presence ofvarious concentrations 
of GnRH (O), [Gln81GnRH (e), chicken  GnRH I1 (VI, [ D - ~ ~ I G ~ R H  (VI, 
and E D - ~ ~ ~ J V - M ~ - L ~ U ~ , P N H E ~ ~ G ~ R H  (El) in COS-1 cells transfected 
with IGin30*lGnRHR, as described under “Materials and Methods.” 
[GIn*]GnRH in  the wild type receptor is due only  to the ability 
of Ar$ t o  stabilize the ligand conformation, then mutation of 
Glu”’ to Gln must have disrupted the conformation of the 
ligand binding site such that  it no longer recognizes the pre- 
ferred ligand conformation. In  this case, both constrained ana- 
logues should bind the wild type receptor with high affinity, 
and both constrained analogues should bind the  mutant 
~~ln3O11GnRHR with low affinity, similar to that of the  mutant 
receptor for unconstrained analogues. Our  results indicate that 
the role of Ar$ is more complex than  either a simple electro- 
static interaction or simple stabilization of the ligand confor- 
mation. Both constrained peptides exhibited high apparent af- 
finity for both the wild type receptor and  the  mutant 
~ G l n ~ i ] ~ n ~ R .  This shows that, although both Arg of the 
ligand and Glu301 ofthe receptor are necessary for high afftnity 
binding of unconstrained ligands, preconstraining the confor- 
mation of the ligand allows high affinity binding in  the absence 
of either or both of these charged residues. This necessity for 
Ar$ and Glu3” only in the absence of a conformational con- 
straint suggests that  an interaction which  involves Ar$ and 
Glu301 induces the high affinity conformation of GnRH. 
The ligand binding sites of heptahelical receptors for small 
ligands such as catecholamines are contained within the hy- 
drophobic transmembrane helices (14, 15, 26). In contrast, 
large amino-terminal domains form the high affinity ligand 
binding sites of receptors for  glycoprotein  hormones (27). Pep- 
tide receptors, including the GnRHR,  do not contain large ami- 
no-terminal domains and the ligand binding sites in these re- 
4 
I * 1 I I 1 
0 10 - 1 1  ,o - fo ,o -910-810-7  ,o -8  ’ 
peptide (M) 
exhibit high  affinity  for  both wild type GnRHR and the 
FIG. 6. Two  conformationalfy  constrained  anaiogues of GnRH 
[GlnSO’JG~Rmutant,Binding~f’~~I-I~-Ala~JV-Me-~u~,Pro~HEt~- 
GnRH (top  panel) in the presence of various concen~rations of 
[ D - ~ ~ , ~ ’ - N H E ~ J G ~ R H  (0, V) and [ D - T ~ ~ ~ , G ~ ~ * , P ~ ’ - N H ~ ~ ] G ~ R H  (0, 
V) to membranes prepared from COS-1 cells transfected with wild type 
GnRHR (- - - -, 0, 0) or rGln3O11G~HR (--, V, V) was measured as 
described under “Materials and Methods.” Data points are the mean +. 
S.E. of three to five experiments performed in triplicate. IP production 
(lower panel)  in response to [ D - T ~ ~ ‘ , P ~ O ~ - N H E ~ ~ G ~ R H  (0, ‘17) and
[D-T~~~,GI~~,P~O’-NHE~]G~RH (m, V) in COS-1 cells transfected with 
wild type GnRHR (- - - -, 0,O) and [Gln3011GnRHR (-, V, ‘I) as de- 
scribed under “Materials and Methods.” Data points are  the means of 
two or three experiments performed in duplicate. 
ceptors appear  to involve residues both in  the transmembrane 
helices (28) and  in  the extracellular domains (29-31). We have 
shown that  the Glu3’’ residue, located in  the third extracellular 
loop  of the GnRHR, plays a major role in determining ligand 
specificity. This confirms the importance of extracellular do- 
mains of receptors for peptide ligands. 
The GIu3Ox residue is conserved in the  rat and mouse Gn- 
RHRs, but  in sheep and  human GnRHRs it i s  replaced with Asp 
(2). This difference indicates that  the length of the side chain is 
probably not critical for the interaction with GnRH, although it 
may contribute to some of the subtle diRerences in pharma- 
cologies  of mammalian GnRHRs (5). Preliminary experiments 
with mutants of the  human GnRHR indicate that substitution 
of AspYo2 with Glu  does  not  affect interaction of the receptor 
with GnRH, whereas substitution with Asn affects the  human 
GnRHR in much the same way as  the GlnS0’ substitution af- 
fects the mouse  GnRHR. 
The [GlnJol]GnRHR shares some  pharmacological character- 
istics with the chicken pituitary GnRHR in that GnRH and 
[Gln8]GnRH display equal activity, whereas chicken  GnRH I1 i s  
more active (5). However, enhancement of activity resulting 
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greater in  the  [G1n3*']G~HR (Table I) than  in  the chicken 
GnRHR (51, suggesting that  the chicken  GnRHR  does not re- 
quire  the same ligand conformation as is required by mamma- 
lian GnRHRs. These results predict that although G;IU~~' is 
likely to  be absent from the chicken  GnRHR, the  latter eceptor 
may have  other  features which increase affinity to compensate 
for the absence of Arg in chicken  GnRHs. 
Our Endings may apply to  other receptors. Vasopressin re- 
ceptors possess an acidic residue in  their  third extracellular 
loop ( G ~ u ~ ~ ~  in  the  human V2 receptor (32)  and Glu323 in the  rat 
V1 receptor (33)) which is not present at the corresponding 
position in the oxytocin receptor (34). Since vasopressins pos- 
sess positively charged residues (Arg or Lys)  which are replaced 
by neutral Leu in oxytocin, it is possible that a similar mech- 
anism may determine the specificity of vasopressin and oxyto- 
cin receptors for their respective ligands. 
In conclusion, we have identified a residue, G1u3", in a mam- 
malian GnRHR  which  confers  specificity  for the Arg at position 
8 of mammalian GnRH. This specificity may result from an 
electrostatic interaction between the 2 residues. Interactions 
which  involve the Glu3" residue of the receptor and the AI$ 
residue of the ligand appear to  induce changes in the confor- 
mation of the ligand. 
A ~ ~ n o w ~ e ~ ~ ~ ~ n t ~ - W e  tha k R. Elario, W. Emeran, and M. Galernbo 
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